Komori
Kringle Pharma (4884) · TargetAdvanced

Transition from a drug-discovery venture to a biopharmaceutical company

First written in 2026-05-14. 8 of 9 entries say "Advanced", first in 2026-05-20. Latest entry: 2026-10-19.

9entries
1years
9from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvanced2026-05-20 – 2026-10-192026: 92026
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
Moved together

"Expanding HGF Indications to Other Diseases by Leveraging Its Mechanism of Action" moved the same way as this thread, in the same document, in 2 of its 9 moves.

22★12
  1. ★This thread
  2. 1Expanding HGF Indications to Other Diseases by Leveraging Its Mechanism of Action2×
  3. 2Monetization through expanded overseas sales and active pharmaceutical ingredient supply2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kringle Pharma yet. It last moved in the Other Disclosures of 2026-10-19: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Transition from a drug-discovery venture to a biopharmaceutical company | Kringle Pharma,Inc. (4884) | Komori